199 related articles for article (PubMed ID: 20799722)
1. Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.
Pandey KK; Bera S; Vora AC; Grandgenett DP
Biochemistry; 2010 Sep; 49(38):8376-87. PubMed ID: 20799722
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.
Bera S; Pandey KK; Vora AC; Grandgenett DP
J Mol Biol; 2011 Jul; 410(5):831-46. PubMed ID: 21295584
[TBL] [Abstract][Full Text] [Related]
3. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
4. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
5. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
6. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
[TBL] [Abstract][Full Text] [Related]
7. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
8. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
[TBL] [Abstract][Full Text] [Related]
9. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
Zahm JA; Bera S; Pandey KK; Vora A; Stillmock K; Hazuda D; Grandgenett DP
Antimicrob Agents Chemother; 2008 Sep; 52(9):3358-68. PubMed ID: 18591263
[TBL] [Abstract][Full Text] [Related]
11. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Johnson BC; Métifiot M; Pommier Y; Hughes SH
Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
[TBL] [Abstract][Full Text] [Related]
13. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
[TBL] [Abstract][Full Text] [Related]
15. MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y
Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054
[TBL] [Abstract][Full Text] [Related]
16. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
[TBL] [Abstract][Full Text] [Related]
17. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
18. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.
Nguyen TT; Rato S; Molina JM; Clavel F; Delaugerre C; Mammano F
J Antimicrob Chemother; 2015 Mar; 70(3):731-8. PubMed ID: 25336162
[TBL] [Abstract][Full Text] [Related]
19. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
